Payers

Five things for pharma marketers to know: Tuesday, July 5, 2016

Five things for pharma marketers to know: Tuesday, July 5, 2016

By

States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

By

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

Intouch Solutions' Weissberg on the rising payer voice

Intouch Solutions' Weissberg on the rising payer voice

By

The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

By

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, March 4, 2016

Five things for pharma marketers to know: Friday, March 4, 2016

By

New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials

Five things for pharma marketers to know: Thursday, March 3, 2016

Five things for pharma marketers to know: Thursday, March 3, 2016

By

Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad

Report Reflects Pharma's Strained Ties with Payers

Report Reflects Pharma's Strained Ties with Payers

By

Payer pressure was once again voted the biggest challenge by respondents, and medium and large biopharma and medical device companies appeared to be most bothered by it.

Omnicom formalizes health group led by CDM's Wise

Omnicom formalizes health group led by CDM's Wise

By

The division, dubbed Omnicom Health Group, claims to serve 70% of the top 100 pharma brands.

The New Patient Centricity Demands Clarity, Community—And Confidence

The New Patient Centricity Demands Clarity, Community—And Confidence

When it came to the issue of patient-centricity, each of us harbored at least a hint of cynicism.

Five things for pharma marketers to know: Tuesday, February 16, 2016

Five things for pharma marketers to know: Tuesday, February 16, 2016

By

Express Scripts revises PCSK9 inhibitor projections; research points to benefits of osteoporosis drugs; doctors consider emotional toll of cancer costs

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

Market Access: Looking Back, Looking Ahead

Market Access: Looking Back, Looking Ahead

Securing market access has become significantly more challenging for pharma marketers.

Healthcare industry says it struggles to define value

Healthcare industry says it struggles to define value

By

If value-based care represents the future of healthcare, it needs a better definition, attendees at an HHS forum said.

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

By

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

By

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky

FDA issues safety warning for AbbVie's HCV drugs

FDA issues safety warning for AbbVie's HCV drugs

By

One analyst said he expects that the change in label "will meaningfully commercially impair Viekira Pak sales."

Lilly kicks off DTC campaign for Trulicity

Lilly kicks off DTC campaign for Trulicity

By

The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.

Six things for pharma marketers to know: Thursday, October 8, 2015

Six things for pharma marketers to know: Thursday, October 8, 2015

By

Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise

Express Scripts to cover Repatha and Praluent

Express Scripts to cover Repatha and Praluent

By

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.

Five things for pharma marketers to know: Wednesday, September 30, 2015

Five things for pharma marketers to know: Wednesday, September 30, 2015

By

Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals

Docs say that off-label use of PCSK9s is premature

Docs say that off-label use of PCSK9s is premature

By

A panel composed of physicians and medical researchers expressed caution in prescribing PCSK9 inhibitors for off-label uses.

Five things for pharma marketers to know: Wednesday, September 23, 2015

Five things for pharma marketers to know: Wednesday, September 23, 2015

By

Turing CEO backs down on price hike; Amgen's and Allergan's cancer biosimilar shows positive results; study finds text message reminders can change health behavior

Price fixing: PBMs push for lower prices of PCSK9 inhibitors

Price fixing: PBMs push for lower prices of PCSK9 inhibitors

By

Now that the first two PCSK9 inhibitors have been given the thumbs-up by the FDA, the payer community finds itself in a situation comparable to the one it faced upon the arrival of transformative hep.-C drugs: What are they prepared to pay—and which drugs will get the formulary nod? Jaimy Lee assesses the fluid market dynamics

Five things for pharma marketers to know: Monday, September 14, 2015

Five things for pharma marketers to know: Monday, September 14, 2015

By

Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

By

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

PCSK9 inhibitors necessitate an update to heart guidelines, CVS Health says

The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines

Five things for pharma marketers to know: Monday, August 10

Five things for pharma marketers to know: Monday, August 10

By

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

By

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

By

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

OPINION

Email Newsletters